TOP NEWS

ROXRO PHARMA Gets $42.7M

Menlo Park-based ROXRO PHARMA, a pharmaceuticals firm developing pain treatments, said today that it has raised $42.7M in a second financing round. The round was led by Prospect Venture Partners and Sutter Hill Ventures; Thomas Weisel Healthcare Venture Partners also participated. ROXCO recently completed Phase 3 clinical trials of its leading compound, a intranasal pain reliever. More information »